Venetoclax

Novel therapies for high-risk MDS 1:41
Novel therapies for high-risk MDS
Sangmin Lee • 4 Jun 2021
Venetoclax and R2 in mantle cell lymphoma 5:50
Venetoclax and R2 in mantle cell lymphoma
Tycel J. Phillips • 20 May 2021
Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL 1:46
Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL
Charles Herbaux • 25 May 2021
Improving outcomes for FLT3-mutated R/R AML 2:26
Improving outcomes for FLT3-mutated R/R AML
Eunice Wang • 27 May 2021
Venetoclax retreatment for CLL 6:50
Venetoclax retreatment for CLL
Meghan Thompson • 28 May 2021
Ivosidenib and venetoclax +/- azacitidine for IDH1-mutated hematologic malignancies 6:51
Ivosidenib and venetoclax +/- azacitidine for IDH1-mutated hematologic malignancies
Curtis Lachowiez • 3 Jun 2021
Dose modification strategies in high-risk MDS treated with venetoclax and azacitidine 2:42
Dose modification strategies in high-risk MDS treated with venetoclax and azacitidine
Uwe Platzbecker • 1 Jun 2021
Liposomal daunorubicin and cytarabine in R/R ALL 7:25
Liposomal daunorubicin and cytarabine in R/R ALL
Bijal Shah • 2 Jun 2021
Novel combinations with ruxolitinib being investigated for myelofibrosis 2:55
Novel combinations with ruxolitinib being investigated for myelofibrosis
Abdulraheem Yacoub • 4 Jun 2021
Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapy 1:55
Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapy
Andrius Zucenka • 7 Jun 2021
Frontline treatment strategies in AML 1:59
Frontline treatment strategies in AML
Andrius Zucenka • 7 Jun 2021
Impact of splicing factor mutations on AML treatment 3:10
Impact of splicing factor mutations on AML treatment
Curtis Lachowiez • 3 Jun 2021
Managing the progression of MDS to AML 2:38
Managing the progression of MDS to AML
Andrew M. Brunner • 3 Jun 2021
Genetic testing in CLL and the role of biomarkers 1:46
Genetic testing in CLL and the role of biomarkers
John Byrd • 3 Jun 2021
Antibody therapies for AML and MDS 2:18
Antibody therapies for AML and MDS
Andrew M. Brunner • 3 Jun 2021
Ponatinib plus venetoclax for R/R Ph+ ALL 3:16
Ponatinib plus venetoclax for R/R Ph+ ALL
Nicholas Short • 25 May 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals